This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, L. Articles by Xing, C. Search for Related Content PubMed PubMed Citation Articles by Wang, L. Articles by Xing, C.

WL-276, an Antagonist against Bcl-2 Proteins, Overcomes Drug Resistance and Suppresses Prostate Tumor Growth

Departments of ¹ Medicinal Chemistry and ² Urology, University of Minnesota, Minneapolis, Minnesota

Requests for reprints: Chengguo Xing, Department of Medicinal Chemistry, University of Minnesota, 8-101 WDH, 308 Harvard Street Southeast, Minneapolis, MN 55455. Phone: 612-626-5675; Fax: 612-624-0139; E-mail: xingx009{at}umn.edu.

Key Words: WL-276 • Bcl-2 • apoptosis • antagonist • drug resistance • HRPC

Patients with hormone-refractory prostate cancer (HRPC) have an estimated median survival of only 10 months because of acquired drug resistance, urging the need to develop therapies against the drug-resistant HRPC phenotype. Accumulating evidence suggests that overexpressing antiapoptotic Bcl-2 family proteins is at least partially responsible for the development of drug resistance among HRPC patients. Antagonizing the antiapoptotic Bcl-2 family proteins, therefore, is one potential approach to circumventing drug resistance in HRPC. WL-276 was developed as a small-molecule antagonist against antiapoptotic Bcl-2 family proteins, with binding potency comparable to (–)-gossypol. Overexpressing Bcl-2 or Bcl-X_L failed to confer resistance to WL-276. WL-276 also effectively induced apoptosis in PC-3 cells. In addition, three PC-3 cell lines with acquired drug resistance against standard cancer chemotherapies were more sensitive to WL-276 than the parent PC-3 cell line. The increased cytotoxicity toward drug-resistant PC-3 cells shows the clinical potential of WL-276 against HRPC that is resistant to conventional therapies. The anticancer activity of WL-276 was manifested in its suppression of PC-3–induced prostate tumor growth in vivo. The selective toxicity of WL-276 against drug-resistant PC-3 cells and its in vivo suppression of PC-3 prostate tumor growth suggest that WL-276 is a promising lead candidate for the development of Bcl-2 antagonists against drug-resistant HRPC. [Cancer Res 2008;68(11):4377–83]

This article has been cited by other articles:

				N. Sasi, M. Hwang, J. Jaboin, I. Csiki, and B. Lu Regulated cell death pathways: New twists in modulation of BCL2 family function Mol. Cancer Ther., June 1, 2009; 8(6): 1421 - 1429. [Abstract] [Full Text] [PDF]